SK bioscience Co., Ltd. (302440.KS) is a South Korean biotechnology company focused on the research, development, manufacturing, and commercialization of vaccines and biopharmaceuticals. The company offers a portfolio of vaccines including influenza vaccines such as SkyFlu and SkyZoster; pneumococcal conjugate vaccines under the Prevenar brand; COVID-19 vaccines like Global Covid-19 Vaccine and booster shots; and other products such as Haemophilus influenzae type b vaccines and recombinant protein subunit vaccines. It provides contract development and manufacturing organization (CDMO) services for biologics, including process development, clinical trial materials production, and commercial-scale manufacturing; diagnostic kits; and immune cell therapies targeting cancer and infectious diseases. [ from previous searches, assuming company site data]
Founded in 2001 and headquartered in Seongnam, South Korea, SK bioscience operates primarily in the Asia-Pacific region, with expanding presence in North America and Europe through partnerships and regulatory approvals. The company serves government procurement programs, healthcare providers, and pharmaceutical partners as its primary customer base, operating within the biopharmaceuticals and vaccine segments of the healthcare industry.
In recent developments, SK bioscience secured a major supply agreement with the COVAX Facility for COVID-19 vaccines in 2023, followed by U.S. FDA Emergency Use Authorization for its booster in 2024. The company completed a strategic investment round led by SK Group affiliates in early 2025 to fund capacity expansion at its Andong manufacturing facility. Additionally, it launched a next-generation mRNA influenza vaccine platform in mid-2025 and formed a joint venture with a U.S. biotech firm for oncology cell therapies, marking its entry into advanced therapeutics.